Literature DB >> 11110706

Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.

S S Mir1, B W Richter, C S Duckett.   

Abstract

CD30 is a member of the tumor necrosis factor (TNF) receptor superfamily that is expressed on activated lymphocytes, as well as on neoplastic cells of Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL). A number of reports have shown that, depending on cellular context, CD30 signaling can exert a variety of effects, ranging from cell death to cellular proliferation. In the present study this disparity was examined, using a number of ALCL- and HD-derived cell lines. Activation of CD30 led to the induction of apoptotic death of ALCL cells, along with the selective reduction of TNF receptor-associated factor 2 and impairment in the ability of these cells to activate the pro-survival transcription factor nuclear factor kappa B (NF-kappa B). In contrast, HD cells, which constitutively express NF-kappa B, were not susceptible to CD30-induced apoptosis but could be sensitized following ectopic overexpression of a superdominant I kappa B. These studies suggest that NF-kappa B plays a determining role in the sensitivity or resistance of lymphoma cells to CD30-induced apoptosis, which may have important consequences in the clinical treatment of CD30-positive neoplasia. (Blood. 2000;96:4307-4312)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110706

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Prognostic factors in pediatric Hodgkin disease.

Authors:  Cindy L Schwartz
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

Review 2.  New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Authors:  Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

Review 3.  Immunotherapies for Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard F Ambinder
Journal:  Crit Rev Oncol Hematol       Date:  2007-11-19       Impact factor: 6.312

Review 4.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

Review 5.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

Review 6.  Targeting CD30 in anaplastic large cell lymphoma.

Authors:  Joseph Vadakara; Barbara Pro
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

8.  Copper is a potent inhibitor of both the canonical and non-canonical NFκB pathways.

Authors:  Niall S Kenneth; George E Hucks; Andrew J Kocab; Annie L McCollom; Colin S Duckett
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

Review 9.  Role of CD30 targeting in malignant lymphoma.

Authors:  Anita Kumar; Anas Younes
Journal:  Curr Treat Options Oncol       Date:  2014-06

10.  Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.

Authors:  Meili Zhang; Zhengsheng Yao; Hiral Patel; Kayhan Garmestani; Zhuo Zhang; Vladimir S Talanov; Paul S Plascjak; Carolyn K Goldman; John E Janik; Martin W Brechbiel; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.